Phase 3 Parkinson's Disease Trial, Completed

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of prostate cancer (adenocarcinoma, not small cell type), confirmed by a tissue or cell sample test.
• People whose prostate cancer has continued to grow or spread while receiving hormone-suppressing treatment (or after having both testicles surgically removed), within the 6 months before joining the trial.
• People who have evidence that their cancer has spread to bones or other parts of the body, confirmed by a bone scan, CT scan, or MRI.
• People who either have never taken the drug abiraterone acetate, took it for at least 4 weeks without their cancer progressing, or took it for at least 8 weeks (or 14 weeks if cancer spread to bones) and then their cancer progressed.
• People whose testosterone levels are being kept very low (below 50 ng/dL) through ongoing hormone-suppressing treatment.
• People taking bone-protecting medications (such as bisphosphonates or denosumab) who have been on a stable dose before joining the trial.
• People who agree to avoid donating sperm and to either abstain from sexual activity or use a condom, during treatment and for at least 90 days after the last dose of the study drug enzalutamide.
• People who can provide a recent tissue biopsy (taken within 12 months of screening) from a soft tissue area that has not been previously treated with radiation, or a bone biopsy if the cancer is mainly in the bones.
• People who are in good general health, able to carry out normal daily activities with little or no limitation (confirmed by a standard health assessment called ECOG score of 0 or 1), assessed within 7 days of joining the trial.

Who may not be able to join:

• People who have another cancer that is still growing or has needed active treatment in the last 3 years.
• People who have an active autoimmune disease (where the immune system attacks the body) that has needed systemic (whole-body) treatment in the past 2 years.
• People who have an immune system deficiency condition, or who are currently taking long-term steroid medication throughout their body.
• People who have had major surgery, including procedures on the prostate (other than a biopsy), within 28 days before joining the trial and have not fully recovered.
• People who have a digestive condition that affects how their body absorbs medications, or who are unable to swallow tablets or capsules.
• People who have an active infection (including tuberculosis) currently requiring treatment.
• People who have a history of, or currently have, a non-infectious lung condition (such as pneumonitis or interstitial lung disease) that needed steroid treatment.
• People who have an active HIV infection, active hepatitis B, or known active hepatitis C infection.
• People who have active cancer spread to the brain or the lining of the brain or spinal cord.
• People who have a known allergy or sensitivity to the study drugs pembrolizumab or enzalutamide, or to any of their ingredients.
• People who have a history of seizures or any medical condition that may increase the risk of seizures.
• People who have lost consciousness at any point in the 12 months before screening.
• People who have very low or uncontrolled high blood pressure at their screening visit (confirm with trial site for exact values).
• People who have a very slow heart rate (fewer than 50 beats per minute) found on a heart tracing (ECG) at screening.
• People whose prostate cancer previously progressed while taking the drug ketoconazole.
• People who have previously been treated with enzalutamide, apalutamide, darolutamide, or certain hormone-blocking drugs other than abiraterone acetate.
• People who have previously received certain types of immunotherapy drugs that work on immune checkpoint pathways (such as anti-PD-1 or anti-PD-L1 treatments).
• People who have previously been treated with radium or other radioactive treatments for prostate cancer.
• People who have previously received chemotherapy such as docetaxel for advanced prostate cancer that no longer responds to hormone treatment.
• People who have previously received certain anti-cancer antibody treatments (monoclonal antibodies) before joining the trial.
• People who have recently used herbal products known to have anti-prostate cancer effects or to lower PSA levels (for example, saw palmetto) before joining the trial.
• People who have received a live or weakened live vaccine within 30 days before joining the trial.
• People who are currently taking part in, or have recently taken part in, another clinical trial involving an experimental treatment or device within the 4 weeks before the first study dose.
• People whose bone scan shows a particular pattern called a "superscan" (confirm with trial site).
• People who are planning to father children from the time of screening through to 90 days after the last dose of enzalutamide.
• People who have received an organ or tissue transplant from another person.

Important: Always verify eligibility with the trial site directly before applying.